Company Overview of Creabilis SA
Creabilis SA, a clinical stage biotechnology company, engages in the research and development of new drugs for the treatment of dermatology and inflammatory diseases. Its development stage product portfolio includes CT327, a TrkA kinase inhibitor for the treatment of psoriasis and atopic dermatitis; CT340, a TrkA kinase and MAP2K3 kinase inhibitor for the treatment of inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for the treatment of inflammatory conditions, such as lupus, acute liver failure, and fibrosis. The company is also involved in various early stage projects for the development of candidates for dermatological and other indications. Creabilis SA was founded in 2003...
5, Rue JeanMonnet
Founded in 2003
Key Executives for Creabilis SA
Chief Development Officer
Compensation as of Fiscal Year 2015.
Creabilis SA Key Developments
Creabilis Appoints Catherine Moukheibir as Chairman of its Board of Directors
Jun 1 15
Creabilis Ltd. has appointed Catherine Moukheibir as Chairman of its Board of Directors. Catherine brings wide experience to Creabilis in aligning corporate goals with financial strategy, allowing companies to continue their strong growth trajectories from a position of financial strength. Catherine is currently a non-executive Board member of Ablynx and Zealand Pharma and a member of the management board of Innate Pharma. Catherine will lead Creabilis' Board at an exciting time for the company as it progresses its lead product CT327.
Creabilis Mulls IPO
Aug 16 14
Creabilis SA intends to go for initial public offering (IPO) later in 2014. Eliot Forster told the Sunday Telegraph he is eyeing a public listing for Creabilis. “We are exploring all options at the moment, but our ambition is to look hard at listing, if we can,” said Forster, adding that he would prefer to float the company in London rather than New York. He said the target fundraising will depend on the scale of trial required to satisfy US regulators.
Creabilis SA Appoints Gil Yosipovitch and Praveen Anand to its Scientific Advisory Board
Jul 29 13
Creabilis SA announced that it has appointed Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board. Gil Yosipovitch is the newly announced Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, and is one of the renowned experts in pruritus. Praveen Anand is Professor of Clinical Neurology and Head of the Centre for Clinical Translation at Hammersmith Hospital, Imperial College London, UK.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 31, 2014
Most Searched Private Companies
Sponsored Financial Commentaries